Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1979
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1989 1
1990 1
1991 1
1992 1
1993 1
1995 2
1996 3
1997 2
1999 1
2000 2
2001 3
2002 1
2003 1
2004 1
2005 3
2007 1
2008 3
2009 2
2012 2
2013 4
2014 2
2015 2
2016 3
2017 4
2018 4
2019 5
2020 3
2021 1
2022 4
2023 6
2024 6
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Epilepsy in neurodegenerative diseases.
Neri S, Mastroianni G, Gardella E, Aguglia U, Rubboli G. Neri S, et al. Epileptic Disord. 2022 Apr 1;24(2):249-273. doi: 10.1684/epd.2021.1406. Epileptic Disord. 2022. PMID: 35596580 Review.
Although epilepsy as a comorbidity in neurodegenerative disorders is increasingly recognized, its incidence is still underestimated and the features of epilepsy in the different neurodegenerative conditions are still poorly defined. Improved health care, resulting i …
Although epilepsy as a comorbidity in neurodegenerative disorders is increasingly recognized, its incidence is still underestimated a …
Recent advances in pharmacotherapy for epilepsy.
Pong AW, Xu KJ, Klein P. Pong AW, et al. Curr Opin Neurol. 2023 Apr 1;36(2):77-85. doi: 10.1097/WCO.0000000000001144. Epub 2023 Feb 10. Curr Opin Neurol. 2023. PMID: 36762638 Review.
The mainstay of therapy is oral medications. Epilepsy drug development is escalating, driven by continued drug resistance in up to a third of epilepsy patients. ...Cenobamate, a first-in-class inactivator of the persistent voltage-gated sodium channel and approved f …
The mainstay of therapy is oral medications. Epilepsy drug development is escalating, driven by continued drug resistance in up to a …
Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, Silvestrini M. Lattanzi S, et al. Drugs. 2018 Nov;78(17):1791-1804. doi: 10.1007/s40265-018-0992-5. Drugs. 2018. PMID: 30390221
The reduction in all-types seizure frequency by at least 50% occurred in 37.2% of the patients in the CBD 20 mg group and 21.2% of the placebo-treated participants [risk ratio (RR) 1.76, 95% CI 1.07-2.88; p = 0.025]. Across the trials, drug withdrawal for any …
The reduction in all-types seizure frequency by at least 50% occurred in 37.2% of the patients in the CBD 20 mg group and 21.2
Advances in the Treatment of Drug-Resistant Pediatric Epilepsy.
Gonzalez-Giraldo E, Sullivan JE. Gonzalez-Giraldo E, et al. Semin Neurol. 2020 Apr;40(2):257-262. doi: 10.1055/s-0040-1702941. Epub 2020 Mar 17. Semin Neurol. 2020. PMID: 32185791 Review.
Epilepsy is a common disorder in children and adults that causes significant morbidity and affects many aspects of a patient's lives. ...The purpose of this review is to provide an overview of recent advancements in the management of treatment-resistant epilepsy
Epilepsy is a common disorder in children and adults that causes significant morbidity and affects many aspects of a patient's
The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.
Orsini A, Valetto A, Bertini V, Esposito M, Carli N, Minassian BA, Bonuccelli A, Peroni D, Michelucci R, Striano P. Orsini A, et al. Seizure. 2019 Oct;71:247-257. doi: 10.1016/j.seizure.2019.08.012. Epub 2019 Aug 23. Seizure. 2019. PMID: 31476531 Free PMC article. Review.
Progressive Myoclonus Epilepsies (PMEs) are a group of uncommon clinically and genetically heterogeneous disorders characterised by myoclonus, generalized epilepsy, and neurological deterioration, including dementia and ataxia. PMEs may have infancy, childhood, juvenile or …
Progressive Myoclonus Epilepsies (PMEs) are a group of uncommon clinically and genetically heterogeneous disorders characterised by myoclonu …
Molecular Mechanisms in Pentanucleotide Repeat Diseases.
Loureiro JR, Castro AF, Figueiredo AS, Silveira I. Loureiro JR, et al. Cells. 2022 Jan 8;11(2):205. doi: 10.3390/cells11020205. Cells. 2022. PMID: 35053321 Free PMC article. Review.
These disorders are clinically heterogeneous being characterized by impaired motor function, resulting from ataxia or epilepsy. The role that apparently normal proteins from these mutant genes play in these pathologies is not known. ...
These disorders are clinically heterogeneous being characterized by impaired motor function, resulting from ataxia or epilepsy. The r …
CBD in the Treatment of Epilepsy.
Borowicz-Reutt K, Czernia J, Krawczyk M. Borowicz-Reutt K, et al. Molecules. 2024 Apr 25;29(9):1981. doi: 10.3390/molecules29091981. Molecules. 2024. PMID: 38731471 Free PMC article. Review.
It has been several years since highly purified cannabidiol (CBD) was registered as a medication that can be used in children of at least 2 years of age to treat different types of seizures related to Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and more recently t …
It has been several years since highly purified cannabidiol (CBD) was registered as a medication that can be used in children of at least …
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Talwar A, Estes E, Aparasu R, Reddy DS. Talwar A, et al. Exp Neurol. 2023 Jan;359:114238. doi: 10.1016/j.expneurol.2022.114238. Epub 2022 Oct 4. Exp Neurol. 2023. PMID: 36206805
However, about one-third of people with epilepsy remain refractory to current ASMs. Cannabidiol (CBD) has recently been approved as ASM for three refractory epilepsy syndrome indications in children and adults. ...Compared with placebo, CBD was associated wit …
However, about one-third of people with epilepsy remain refractory to current ASMs. Cannabidiol (CBD) has recently been approved as A …
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Lattanzi S, Trinka E, Russo E, Del Giovane C, Matricardi S, Meletti S, Striano P, Damavandi PT, Silvestrini M, Brigo F. Lattanzi S, et al. Drugs. 2023 Oct;83(15):1409-1424. doi: 10.1007/s40265-023-01936-y. Epub 2023 Sep 11. Drugs. 2023. PMID: 37695433 Free PMC article.
BACKGROUND: Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy characterized by drug-resistant, lifelong seizures. The management of seizures in DS has changed in recent years with the approval of new antiseizure medications (ASMs). ...RESULTS: Eig …
BACKGROUND: Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy characterized by drug-resistant, lifelong sei …
Cannabinoids for epilepsy: What do we know and where do we go?
Brodie MJ, Ben-Menachem E. Brodie MJ, et al. Epilepsia. 2018 Feb;59(2):291-296. doi: 10.1111/epi.13973. Epub 2017 Dec 6. Epilepsia. 2018. PMID: 29214639 Review.
Over the past decade there has been an increasing interest in using cannabinoids to treat a range of epilepsy syndromes following reports of some remarkable responses in individual patients. ...Nevertheless, recent randomized, placebo-controlled trials with cannabid …
Over the past decade there has been an increasing interest in using cannabinoids to treat a range of epilepsy syndromes follow …
69 results